Iliana Higareda

Hospital Civil de Guadalajara

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gail L. Woods

University of South Alabama Medical Center

Albert E. Yellin

University of Southern California

Ben Adeyi

Takeda (United States)

Mahmoud Ismail

South Valley University

Subir Roy

University of Southern California

Richard Gesser

Sanofi (United States)

Blaise L. Congeni

Akron Children's Hospital

Jeffrey P. Johnson

Columbia University Irving Medical Center

EÁ

Edith Ángel‐Müller

Universidad Nacional de Colombia

Antonio Arrieta

Children's Hospital of Orange County

Cooperative Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States)

United States Military Academy

Arkansas Children's Hospital

University of Southern California

LAC+USC Medical Center

University of California, Irvine

Los Angeles Medical Center

Children's Hospital of Los Angeles

Southern California University for Professional Studies

Merck (France)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind Study

Infectious Diseases in Obstetrics and Gynecology (2002)

Subir Roy Iliana Higareda Edith Ángel‐Müller Mahmoud Ismail Caren Hague

To compare ertapenem therapy with piperacillin-tazobactam therapy for the management of acute pelvic infections.In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin-tazobactam, 3.375 g every 6 hours, both administered intravenously.In total, 163 patients in the ertapenem group and 153 patients in the piperacillin-tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli. At the primary efficacy endpoint 2-4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin-tazobactam were cured (95% confidence interval for the difference, adjusting for strata, -4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups.In this study, ertapenem was as effective as piperacillin-tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin-tazobactam.

Ertapenem

Piperacillin/tazobactam

Tazobactam

Multicenter trial

10.1155/s1064744903000048

Cite

Citations (57)

Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients

The American Journal of Surgery (2007)

Albert E. Yellin Jeffrey P. Johnson Iliana Higareda Blaise L. Congeni Antonio Arrieta

Ertapenem

Ticarcillin

Tolerability

Carbapenem

10.1016/j.amjsurg.2007.01.023

Cite

Citations (25)